Abstract
Prescriptions for opioid analgesics to manage moderate-to-severe chronic non-cancer pain have increased markedly over the last decade. An unintentional consequence of greater prescription opioid utilization has been the parallel increase in misuse, abuse and overdose, which are serious risks associated with all opioid analgesics. In response to disturbing rises in prescription opioid abuse, the US Food and Drug Administration (FDA) has proposed the implementation of aggressive Risk Evaluation and Mitigation Strategies (REMS). While REMS could dramatically change the development, release, marketing and prescription of extended-release opioids, questions remain on how these programmes may influence prescribing practices, patient safety and ultimately patient access to these agents. The extent of the availability and misuse of prescription opioids in Europe is difficult to assess from the data currently available, due in large part to the considerable differences in prescribing patterns and regulations between countries. Balancing the availability of prescription opioids for those patients who have pain, while discouraging illicit use, is a complex challenge and requires effective efforts on many levels, particularly in Europe where policies are quite different between countries.
Similar content being viewed by others
References
Reid MC, Engles-Horton LL, Weber MB, et al. Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med 2002; 17: 173–9
Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 287–333
Zorba Paster R. Chronic pain management issues in the primary care setting and the utility of long-acting opioids. Expert Opin Pharmacother 2010; 11: 1823–33
Chou R, Fanciullo GJ, Fine PG, et al. Opioid treatment guidelines: clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10: 113–30
Rosenblum A, Joseph H, Fong C, et al. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA 2003; 290: 2370–8
Gudin JA. The changing landscape of opioid prescribing and extended-release opioid class-wide risk evaluation and mitigation strategy. Ther Clin Risk Manage 2012; 8: 209–17
Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern med 2010; 152: 85–92
Summary minutes of the joint meeting of the Anesthetic and Life Support Drugs Advisor Committee (ALSDAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM); July 22–23, 2010; Adelphi (MD) [online]. Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM224672.pdf [Accessed 2012 Oct 1]
Robert Lowes. Tighten opioid label restrictions, physicians tell FDA [online]. Available from URL: http://www.medscape.com/viewarticle/768214 [Accessed 2012 Oct 24]
Chou R, Fanciullo GJ, Fine PG, et al. American Academy of pain medicine opioids guidelines panel: clinical guidelines for the use of chronic opioid therapy in chronic non-cncer pain. J Pain 2009; 10: 113–30
Fishbain DA, Cole B, Lewis J, et al. What percentage of chronic non malignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/ or aberrant drug-related behaviours? Pain Med 2008; 9: 444–59
Hojsted J, Sjogren P. Addiction to opioids in chronic pain patients: a literature review. Eur J Pain 2007; 11: 490–518
Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid-overdose deaths. JAMA 2011; 305: 1315–21
Argoff CE, Passik SD. Abuse-deterrent opioid formulations: from science to practice [online]. Available from URL: http://www.medscape.org/viewarticle/705952 [Accessed 2012 Oct 24]
Shane R. Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems. Am J Health Syst Pharm 2009 15; 66 (24 Suppl. 7): S6–12
Gudin J. References risk evaluation and mitigation strategies (REMS) for extended-release and long-acting opioid analgesics: considerations palliative care practice. J Pain Palliate Care Pharmacother 2012; 26: 136–43
Nicholson S, Peterson J, Yektashenas B. Pharmaceutical industry perspective on risk evaluation and mitigation strategies: manufacturer take heed. Expert Opin Drug Saf 2012; 11: 299–314
US Department of Health and Human Services. US FDA. FDA opioid REMS meeting with industry (May 16, 2011) [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm258184.htm [Accessed 2012 Oct 1]
US Food and Drug Administration, Approved risk evaluation and mitigation strategies (REMS) December 12, 2011 update. [online]. Available from URL: http://www.pharmasug.org/proceedings/2012/IB/PharmaSUG-2012-IB02.pdf [Accessed 2012 Oct 1]
Craig DS. Are opioid risk evaluation and mitigation strategies (REMS) interrupting your sleep? J Pain Palliat Care Pharmacoth 2012; 26: 134–5
Fiore K. Critics: opioid REMS misses mark on patient education. Medpage TODAY, 2012 Aug 1 [online]. Available from URL: http://www.medpagetoday.com/InOtherWords/33938 [Accessed 2012 Oct 1]
Centers for Disease Control and Prevention. Prescription painkiller overdoses: methadone [online]. Available from URL: http://www.cdc.gov/features/vitalsigns/methadoneoverdoses/ [Accessed 2012 Oct 1]
Slevin KA, Ashburn MA. Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies. J Opioid Manag 2011; 7: 109–15
Substance Abuse and Mental Health Services Administration. Results fromthe2010 nationalsurvey ondrug use and health: summary of national findings. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2011-NSDUH Series H-41, HHS Publication No. (SMA) 11-4658
Peppin JF, Coleman JJ, Kirsh KL. Issues and critiques of the forthcoming risk evaluation and mitigation strategy (REMS) for opioids in pain management. Issues Law Med 2011; 27: 91–119
OPEN Minds. The white paper on opioids and pain: a pan-European challenge. 2005 Jun [online]. Available from URL: http://www.dgss.org/fileadmin/pdf/50616_White_Paper.pdf [Accessed 2012 Oct 1]
Cherny NI, Baselga J, de Conno F, et al. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative. Ann Oncol 2010; 21: 615–26
Hutchinson K, Moreland A, de Williams A, et al. Exploring beliefs and practice of opioid prescribing for persistent non-cancer pain by general practitioners. Eur J Pain 2007; 11: 93–8
European Monitoring Centre for Drugs and Drug Addiction. 2010 Annual report on the state of the drugs problem in Europe. Lisbon: EMCDDA, 2010 Nov [online]. Available from URL: http://www.emcdda.europa.eu/publications/annual-report/2010 [Accessed 2012 Oct 1]
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mercadante, S., Craig, D. & Giarratano, A. US Food and Drug Administration’s Risk Evaluation and Mitigation Strategy for Extended-Release and Long-Acting Opioids. Drugs 72, 2327–2332 (2012). https://doi.org/10.2165/11642230-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11642230-000000000-00000